MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents

NCT03217097 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: Oxaliplatin-based chemotherapy
DRUG: Alkylating-based chemotherapy

Sponsor

Hospices Civils de Lyon